VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback that supports the company's proposed development strategy for its lead BiTAC(R)-TCE program. This early guidance from the PEI addresses the biological rationale, safety assessments, and non-clinical development plan for VERAXA's novel therapeutic platform, which is designed to harness bispecific T-cell engagers for cancer treatment.
The Scientific Advice procedure allows drug developers to consult with regulatory experts before initiating clinical trials, helping to align development strategies with regulatory expectations. According to the company, this feedback reduces development uncertainty by providing greater clarity on the path forward. VERAXA believes that the positive regulatory input strengthens its position as it prepares to advance its BiTAC(R)-TCE candidate toward clinical studies.
The lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data, which was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The company continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. This latest regulatory milestone follows continued progress in manufacturing and development as VERAXA advances next-generation antibody therapeutics for cancer.
VERAXA Biotech, an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform. The announcement signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).
The company's focus on bispecific T-cell engagers represents a promising approach to cancer immunotherapy, leveraging the body's immune system to target and destroy tumor cells. With the regulatory feedback from PEI, VERAXA is better positioned to navigate the complex development pathway required for bringing such therapies to patients.
